State Street SPDR S&P Pharmaceuticals ETF

XPH

市值 US$4.48億

Pharmaceuticals/biotechnology are currently overvalued by 14% versus 11-year averages, while healthcare equipment appears undervalued despite recent value score deterioration. State Street SPDR S&P Pharmaceuticals ETF offers diversified pharma exposure with low company-specific risk due to its modified equal-weight methodology. XPH is best suited for tactical allocation or swing trading, not as a compelling long-term holding, given its historical risk-return profile and sector dynamics.

The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S. Pharmaceuticals ETF provides a higher dividend yield of 1.4% compared to 0.4% for the State Street SPDR S&P Pharmaceuticals ETF.

The VanEck Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF both carry an identical expense ratio of 0.35%. The State Street SPDR S&P Pharmaceuticals ETF is more diversified with 62 holdings, while the VanEck Biotech ETF focuses on 25 holdings.

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on June 19, 2006.

Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.

iShares Global Healthcare ETF provides broad sector coverage with a higher dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered stronger total returns over the last year but experiences significantly higher maximum drawdowns.

The Vanguard Health Care ETF offers a significantly lower expense ratio and a higher dividend yield than the State Street SPDR S&P Pharmaceuticals ETF. The State Street SPDR S&P Pharmaceuticals ETF provides concentrated exposure to drug manufacturers, while the Vanguard Health Care ETF covers a broader range of medical services and equipment.

Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.35% charged by State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF focuses specifically on the pharmaceutical industry, whereas Fidelity MSCI Health Care Index ETF tracks the broader healthcare sector.

Subscribers to  Chart of the Week  received this commentary on Sunday, Sept.

The State Street SPDR S&P Pharmaceuticals ETF offers a significantly lower expense ratio of 0.35% compared to the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF provides a more concentrated portfolio of 29 stocks and lower price volatility as measured by beta.